Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04568083 · ClinicalTrials.gov registry record
Patient Characteristics, Persistence to Treatment and Outcome Events in Patients Treated With Ticagrelor 60 mg After Myocardial Infarction in Real-world Clinical Practice
A clinical trial, sponsored by AstraZeneca.
- Completed
- Registry status
- 7,035
- Enrollment target
NCT04568083: Completed study, sponsored by AstraZeneca.
NCT04568083 is a clinical trial that has completed, run by AstraZeneca. The registered enrollment target is 7,035 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04568083 has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- 7,035 participants
- Enrollment target
Study Summary
This is an observational study based on secondary data extracted from multiple register-based data sources in the US and Europe (Sweden, United Kingdom, Italy, Germany). The study will include patients initiating treatment with ticagrelor 60 mg after a myocardial infarction in real-world clinical practice, and describe their patient characteristics and duration of treatment. If the a priori threshold of 5,000 person-years on treatment with ticagrelor 60 mg is met, outcome events (bleeding and cardiovascular events) will also be analysed and described.
Primary Outcome
Treatment discontinuation is defined on the basis of calculated days of supply from prescription data.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7,035 participants |
| Start Date | 2020-09-25 |
| Est. Completion | 2021-06-28 |
What the finished NCT04568083 record still lists
NCT04568083 is an observational study that tracks outcomes without assigning an intervention. Its 7,035 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT04568083 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04568083 about?
NCT04568083 is a clinical study titled "Patient Characteristics, Persistence to Treatment and Outcome Events in Patients Treated With Ticagrelor 60 mg After Myocardial Infarction in Real-world Clinical Practice". This is an observational study based on secondary data extracted from multiple register-based data sources in the US and Europe (Sweden, United Kingdom, Italy, Germany). The study will include patients initiating treatment with ticagrelor 60 mg after a myocardial infarction in real-world clinical pr...
What is the current status of trial NCT04568083?
This trial is currently completed. The enrollment target is 7,035 participants. The study started on 2020-09-25. Estimated completion is 2021-06-28.
Who is sponsoring clinical trial NCT04568083?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00260585 · 7,000 participants
Esophageal Cancer Risk Registry
- NCT04118660 · 7,000 participants
Thoracic Specimen Registry
- NCT07106879 · 7,000 participants
Non-interventional Pre-screening Protocol Aims to Evaluate Participants for Potential Trial Eligibility in Future Clinical Trials/Studies Focusing on Metabolic and Psychiatric Health.
- NCT07140744 · 7,000 participants · NA
A Study Evaluating the Impact of P-tau217 Blood Biomarker Testing on Early Evaluation and Management of Patients Presenting With Cognitive Complaint
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI